Ranibizumab Pro Re nata versus Dexamethasone in the Management of Ischemic Retinal Vein Occlusion: Post-hoc Analysis from the COMRADE Trials

Amelie Pielen,Nicolas Feltgen,Lars-Olof Hattenbach,Hans Hoerauf,Thomas Bertelmann,Claudia Quiering,Jessica Vögeler,Siegfried G. Priglinger,Gabriele E. Lang,Steffen Schmitz-Valckenberg,Armin Wolf,Matus Rehak

Ranibizumab Pro Re nata versus Dexamethasone in the Management of Ischemic Retinal Vein Occlusion: Post-hoc Analysis from the COMRADE Trials

2019

Amelie Pielen
Nicolas Feltgen
Lars-Olof Hattenbach
Hans Hoerauf
Thomas Bertelmann
Claudia Quiering
Jessica Vögeler
Siegfried G. Priglinger
Gabriele E. Lang
Steffen Schmitz-Valckenberg
Armin Wolf
Matus Rehak

ABSTRACTPurpose: To compare ischemia-related clinical outcomes in patients treated with either ranibizumab pro re nata (PRN) or single dexamethasone implant in the Branch Retinal Vein Occlusion (CO...

Keywords:

Retinal Vein
Ranibizumab
Occlusion
Diabetes mellitus
Ophthalmology
Anatomy
Pro re nata
Dexamethasone
Post-hoc analysis
Biology
Macular degeneration
Branch retinal vein occlusion

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations